findmyKOL
Clinical trialNCT04712851RecruitingPhase 2Interventional

Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

SponsorJonsson Comprehensive Cancer CenterEnrollment25Cervical Intraepithelial NeoplasiaCervical Squamous Cell Carcinoma In SituCervical Squamous Intraepithelial Neoplasia 2
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial studies the effect of pembrolizumab on cervical intraepithelial neoplasia. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of California at Los Angeles / Jonsson Comprehensive Cancer Center

    Los Angeles, California, United States

    John A. Glaspy, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Pembrolizumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Jun 2021
Primary completion
31 Jan 2027
Completion
31 Jan 2028
Last update posted
10 Mar 2026
Registered enrollment
25
Registry id
NCT04712851
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.